Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
MaxCyte ( (MXCT) ) has issued an announcement.
MaxCyte, Inc. announced a change in its major holdings, with BlackRock, Inc. increasing its voting rights in the company to 9.98%. This adjustment in BlackRock’s stake could potentially influence MaxCyte’s strategic decisions and market positioning, reflecting confidence from a significant institutional investor.
More about MaxCyte
MaxCyte, Inc. operates in the biotechnology industry, focusing on cell-based therapies and providing cell-engineering platforms. The company is known for its proprietary flow electroporation technology, which is used in the development of advanced medicines.
Find detailed analytics on MXCT stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue